CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer

Lung Cancer

Volumn 69, Issue 3, 2010, Pages 355-360

  Miotto, D ^a   Cascio, N Lo ^a   Stendardo, M ^a   Querzoli, P ^a   Pedriali, M ^a   De Rosa, E ^a   Fabbri, L M ^b   Mapp, C E ^a   Boschetto, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Interleukin 10; Nonsmall cell lung cancer; Survival

Indexed keywords

INTERLEUKIN 10;

ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LUNG CANCER; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 77955093008     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.12.012     Document Type: Article

References (37)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
2. Ellyard J.I., Samson L., Parish C.R. Th2-mediated anti-tumour immunity: friend or foe?. Tissue Antigens 2007, 70:1-11.
3. Mantovani A., Sica A., Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007, 37:14-16.
4. Kim D.W., Min H.S., Lee K.H., Kim Y.J., Oh D.-Y., Jeon Y.K., et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer 2008, 98:1118-1124.
5. Chen J.J., Yao P.L., Yuan A., Hong T.M., Shun C.T., Kuo M.L., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003, 9:729-737.
6. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., et al. Predominant infiltration of macrophages and CD8+T cells in cancer nest is a significant predictor of survival in stage IV non small cell lung cancer. Cancer 2008, 113:1387-1395.
7. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
8. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
9. Wakabayashi O., Yamazaki K., Oizumi S., Hommura F., Kinoshita I., Ogura S., et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003, 94:1003-1009.
10. Huang Y., Obholzer N., Fayad R., Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol 2005, 175:3110-3116.
11. Moreno M., Molling J.W., von Mensdorff-Pouilly S., Verheijen R.H., Hooijberg E., Kramer D., et al. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 2008, 181:2446-2454.
12. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002, 195:695-704.
13. Wang R.F. CD8(+) regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008, 69:811-814.
14. Mocellin S., Marincola F.M., Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005, 78:1043-1051.
15. Hatanaka H., Abe Y., Kamiya T., Morino F., Nagata J., Tokunaga T., et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 2000, 11:815-819.
16. Soria J.C., Moon C., Kemp B.L., Liu D.D., Feng L., Tang X., et al. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2003, 9:1785-1791.
17. Buist S. Introduction. Proc Am Thor Soc 2008, 5:796-799.
18. Saetta M., Turato G., Maestrelli P., Mapp C.E., Fabbri L.M. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1304-1309.
19. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
20. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
21. Mountain C.F. Revision in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
22. Zhu J., Qiu Y., Valobra M., Qiu S., Majumdar S., Matin D., et al. Plasma cells and interleukin-4 in chronic bronchitis and COPD. Am J Respir Crit Care Med 2007, 175:1125-1133.
23. Saetta M., Di Stefano A., Turato G., Facchini F.M., Corbino L., Mapp C.E., et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:822-826.
24. Chinn S. Statistics in respiratory medicine. 2. Repeatability and method comparison. Thorax 1991, 46:454-456.
25. Gadgeel S.M., Ramalingam S., Cummings G., Kraut M.J., Wozniak A.J., Gaspar L.E., et al. Lung cancer in patients <50 years of age: the experience of an academic multidisciplinary program. Chest 1999, 115:1232-1236.
26. Birim O., Kappetein A.P., van Klaveren R.J., Bogers A.J.J.C. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006, 32:12-23.
27. López-Encuentra A., Astudillo J., Cerezal J., Gonzalez-Aragoneses F., Novoa N., Sánchez-Palencia A. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg 2005, 27:8-13. Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).
28. Jarnicki A.G., Lysaght J., Todryk S., Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006, 15(177):896-904.
29. Meloni F., Morosini M., Solari N., Passadore I., Nascimbene C., Novo M., et al. Foxp3 expressing CD4+ CD25+ and CD8+ CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006, 7:1-12.
30. Erdman S.E., Rao V.P., Poutahidis T., Ihrig M.M., Ge Z., Feng Y., et al. CD4+ CD25+ regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003, 63:6042-6050.
31. Voboril R., Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma 2007, 54:495-502.
32. Kundu N., Fulton A.M. Interleukin-10 inhibits tumor metastasis, down-regulates MHC class I, and enhances NK lysis. Cell Immunol 1997, 180:55-61.
33. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005, 17:180-186.
34. Kiniwa Y., Miyahara Y., Wang H.Y., Peng W., Peng G., Wheeler T.M., et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007, 13:6947-6958.
35. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001, 2:725-731.
36. Kataki A., Scheid P., Piet M., Marie B., Martinet N., Martinet Y., et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002, 140:320-328.
37. Zeni E., Mazzetti L., Miotto D., Lo Cascio N., Maestrelli P., Querzoli P., et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007, 30:608-610.